In­hibikase shelves Parkin­son’s as­set af­ter Phase 2 flop

In­hibikase Ther­a­peu­tics is slam­ming the brakes on its Parkin­son’s dis­ease pro­gram af­ter the can­di­date failed to im­prove symp­toms in a mid-stage test in treat­ment-naïve pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER